Canon BioMedical said today it has inked an exclusive distribution agreement with Molecular Biology Systems (MBS) to market and sell its NEXTGENPCR instrument, consumables, and accessories in the United States and Canada.
Under the agreement, whose value was not disclosed, Canon BioMedical agreed to distribute the NEXTGENPCR instrument, as well as related consumables, and associated accessories.
The instrument—whose name is derived from “next-generation polymerase chain reaction”—is designed to reduce the DNA amplification procedure from hours to just minutes. It is a three-step, 30-cycle protocol to amplify a 100-base pair fragment that can be completed in less than two minutes, according to Canon BioMedical, compared with between 50 and 150 minutes for traditional PCR instruments that have relied on Peltier elements to heat and cool an aluminum or silver block, accommodating 96 or 384 polypropylene tubes holding PCR-mixes.
Canon BioMedical said it will initially distribute the NEXTGENPCR instrument in the U.S., at multiple upcoming conferences. In September, MBS announced a series of distribution deals, of undisclosed value, with PreMed Lab of China, Pronto Diagnostics of Israel, Ybux of the Czech Republic, Albiogen of Russia, Camlab of the U.K., and Isogen Life Science, which has operations in the Netherlands, Belgium, and Spain.
“MBS shares in our commitment to high-quality products that improve the laboratory experience. Researchers want answers as fast as possible, and offering the NEXTGENPCR products to our customers will shorten their protocols without requiring them to change their procedures,” Dennis Snyder, senior director of global commercial operations for Canon BioMedical, said in a statement.
Added MBS CEO and founder Gert de Vos, “We believe that Canon BioMedical can make NEXTGENPCR a market leader in the United States and Canada. We are happy that Canon BioMedical recognizes the innovation, quality design, and reduced environmental impact of our NEXTGENPCR products.”